Data completeness
0/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEN-K is an oral extended-release small molecule tablet in pre-launch development by Novartis under NDA review. The mechanism of action, indication(s), and pharmacologic class are not yet disclosed in public filings. Patient population and clinical utility remain to be determined upon regulatory approval.
Pre-Launch
Pre-commercial stage with significant team-building opportunity; expect rapid scaling upon NDA approval with roles in regulatory affairs, market access, and launch planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TEN-K offers early-stage pharma career momentum with high visibility during a pivotal launch phase. Novartis backing and pre-approval positioning create opportunities to shape market strategy from ground zero, though long-term career security depends on successful NDA approval and commercial performance.
Regulatory Affairs ManagerBrand Manager
Worked on TEN-K at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.